From a translational point of view, a better characterization of BPIFB4 clinical relevance by investigating its expression in damaged tissues or PBMCs obtained from COVID-19 patients will help to validate BPIFB4 as a valuable biomarker for COVID-19 severity. This evidence concerns the gene BPIFB4 and COVID-19.